Swiss pharma company Idorsia shares plunge 45%

To the annoyance of shareholders, shares in Idorsia were down 45% on Friday (Dec. 20) after the company announced delays to a rights deal related to its hypertension drug Tryvio. On November 27, 2024, the Allschwil-based company announced that it had entered exclusive negotiations with an undisclosed party for global rights to aprocitentan, sold under the brand name Tryvio, that resulted in

READ MORE